Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.
Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...
PathoQuest’s Paris-based Facility Obtains GLP Certificate for the Company’s Biologics Genomic Quality Control Testing Service
Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE, January 23, 2020 – PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the...
PathoQuest Secures 8 Million Euros in New Financing
Paris, FRANCE -- (BUSINESS WIRE) -- September 5, 2019 -- PathoQuest, a genomic expert company dedicated to the microbiology testing market and a leader in clinical diagnostics and biologics testing applications, today announces the closing of an 8M euros financing...
PathoQuest Names Dr. Christiane Honisch to Board of Directors
PARIS, FRANCE – September 25, 2018 -- PathoQuest, a genomic expert dedicated to the microbiology testing market, leader in clinical diagnostics and biologics testing applications, today announced the appointment of Christiane Honisch, Ph.D. as an...
PathoQuest Announces New Appointments to Executive Leadership Team
Company adds experienced executives to support the continued growth of Biologics Genomic Service and Clinical Diagnostics businesses which utilize PathoQuest’s proprietary Next-Generation Sequencing (NGS) based testing solution. PARIS, FRANCE – July 10,...
PathoQuest announces enrollment of first patient in IDENTIFY, a prospective clinical study assessing the medico-economic benefit of iDTECT™ Blood for the diagnosis of bloodstream infection in immunocompromised patients
Pour la version en français de ce communiqué de presse : cliquez ici PARIS, FRANCE, May 22, 2018 – PathoQuest, a genomic expert for biologics testing and a leader in improving pathogen identification in clinical biological samples, today announced the...
Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership
Partnership Charles River will provide clients access to PathoQuest’s NGS-based testing solutions WILMINGTON, MA and PARIS, FRANCE, April 9, 2018 – Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest today announced an expansion of...
PathoQuest and Mayo Clinic Enter into an Agreement to Conduct Study of iDTECT™ Blood in Patients with Febrile Neutropenia
Pour la version en français de ce communiqué de presse : cliquez ici PathoQuest, a life sciences leader focused on improving pathogen identification in biological samples, today announced that it will conduct research with Mayo Clinic to study the...
PathoQuest Announces Formation of Scientific Advisory Board
Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts. The Scientific Advisory Board will advise PathoQuest in its Research and Development efforts in metagenomics applied to...
PathoQuest Collaborating with Memorial Sloan Kettering Cancer Center to study iDTECT™ Blood in patients with febrile neutropenia
Pour la version en français de ce communiqué de presse : cliquez ici PathoQuest, a life sciences leader focused on improving pathogen detection in biological samples, today announced that it has entered into an agreement with Memorial Sloan Kettering...